S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

WINT Windtree Therapeutics Inc

0.3656

-0.0144 (-3.79%)

Last Updated: 02:32:22

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Windtree Therapeutics (NASDAQ:WINT)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Windtree Therapeutics Charts.

Windtree Therapeutics (NASDAQ:WINT)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Windtree Therapeutics Charts.

Windtree Therapeutics Inc News

Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference
Tuesday 17 December 2024 (2 days ago) • GlobeNewswire Inc.

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia
Tuesday 10 December 2024 (1 week ago) • GlobeNewswire Inc.

Form 8-K - Current report
Thursday 5 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 5 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction
Thursday 5 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Thursday 28 November 2024 (3 weeks ago) • Edgar (US Regulatory)

Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates
Thursday 28 November 2024 (3 weeks ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 15 November 2024 (1 month ago) • Edgar (US Regulatory)

Windtree Announces Leadership Transition Plan With Industry Veterans
Friday 15 November 2024 (1 month ago) • GlobeNewswire Inc.

Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong
Tuesday 5 November 2024 (1 month ago) • GlobeNewswire Inc.

Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3
Wednesday 30 October 2024 (2 months ago) • GlobeNewswire Inc.

More Windtree Therapeutics Inc News Articles

Westpac Banking

S&P ASX 300 Metals and M...

Newcrest Mining

Verizon Communications

National Australia Bank

AUD vs US Dollar

JP Morgan Chase

Sterling vs AUD

Commonwealth Bank Of Aus...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions